BiotechTube
Home/Pipeline/ANAVEX®1066

ANAVEX®1066

Not Specified

Discovery/PreclinicalDiscovery

Key Facts

Indication
Not Specified
Phase
Discovery/Preclinical
Status
Discovery
Company
Anavex Life Sciences

About Anavex Life Sciences

Anavex Life Sciences is a clinical-stage biotech focused on developing oral therapeutics for central nervous system (CNS) disorders by targeting the sigma-1 receptor (SIGMAR1). Its lead asset, blarcamesine, has generated pivotal clinical data in Alzheimer's disease and holds Orphan Drug Designation for Rett syndrome, positioning it in multi-billion dollar markets with high unmet need. The company operates with a lean, virtual model, advancing a precision medicine platform that aims to modify disease pathology rather than just alleviate symptoms.

View full company profile

Therapeutic Areas

Neurodegenerative DiseasesNeurodevelopmental Disorders

Other Not Specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN022AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved